Lithium Decreases Sodium Less Than Depakote
Lithium is less likely to decrease serum sodium compared to valproic acid (Depakote). Valproate is specifically documented to cause hyponatremia through a syndrome of inappropriate antidiuretic hormone secretion (SIADH)-like mechanism, while lithium's effects on sodium are primarily related to renal handling rather than direct sodium reduction 1, 2.
Evidence for Valproate-Induced Hyponatremia
The FDA drug label for Depakote explicitly lists hyponatremia and inappropriate ADH secretion as recognized endocrine adverse effects 1. This is not merely theoretical—clinical case reports demonstrate dose-dependent hyponatremia with valproate. In one documented case, a patient developed serum sodium of 128 mEq/L on 2,000 mg/day of sodium valproate, with water loading tests confirming reduced water excretion ability that varied directly with valproate dosage 2. This SIADH-like syndrome requires monitoring of serum sodium levels, particularly at higher doses.
Lithium's Sodium Effects Are Different
While lithium does affect electrolyte balance, its mechanism differs fundamentally from valproate. Lithium primarily causes:
- Nephrogenic diabetes insipidus (leading to hypernatremia risk, not hyponatremia)
- Renal sodium wasting (which can lower sodium, but through a different mechanism)
- Potential for bradycardia and cardiac conduction changes 3
The cardiovascular guidelines note lithium requires monitoring but do not highlight hyponatremia as a primary concern 3. Lithium's interaction with sodium is bidirectional—low sodium states can increase lithium toxicity risk, but lithium itself is not primarily associated with causing clinically significant hyponatremia through SIADH mechanisms.
Clinical Monitoring Implications
For patients on valproate: Monitor serum sodium levels, especially when:
- Using doses >1,500-2,000 mg/day
- Patient develops confusion or altered mental status
- Combining with other medications that affect sodium or ADH
For patients on lithium: Monitor:
- Lithium levels (therapeutic range 0.6-1.2 mEq/L)
- Renal function and electrolytes
- Thyroid function
- ECG if cardiac risk factors present
Important Caveat
Both medications require comprehensive metabolic monitoring, but the specific risk of SIADH-induced hyponatremia is documented and dose-dependent with valproate 1, 2, making it the more concerning agent for sodium reduction. This distinction is clinically relevant when choosing between these mood stabilizers for patients with baseline hyponatremia, those on diuretics, or elderly patients at higher risk for electrolyte disturbances.